Table 1.
Protein | Domain architecture | Tudor ligand | Kd (μM) | Biological functions | Ref. |
---|---|---|---|---|---|
JMJD2A | H3K4me3 | ~0.5 | H3K9me3 and H3K36me3- specific demethylase; transcriptional regulation and regulator of DNA damage response | 28, 45, 48 | |
H4K20me3 | ~0.4 | ||||
H4K20me2 | ~2 | ||||
53BP1 | H4K20me2 | 20~50 | substrate of ATM; promote non-homologous end joining DNA repair | 29, 44 | |
SGF29 | H3K4me3 | 1~4 | component of SAGA complex; mediate transcriptional activation | 30, 31 | |
Spindlin1 | H3K4me3 | ~0.8 | nucleolar protein; promote rRNA transcription | 32, 33 | |
UHRF1 | H3K9me3 by Tudor | 1~3 | partner of DNMT1; maintain the level of DNA methylation during DNA replication | 35, 37, 66, 88, 89 | |
H3 N-terminus& K9me3 byTudor-PHD | ~0.4 | ||||
PHF1 | H3K36me3 | 5~50# | accessory component of PRC2 complex; promote transcriptional repression | 38, 39, 40 | |
PHF19 | H3K36me3 | 6~35# | accessory component of PRC2 complex; promote transcriptional repression | 38, 40, 41, 42 | |
LBR | H4K20me2 | N.D. | inner nuclear membrane protein; promote formation of nuclear peripheral heterochromatin | 84 | |
TDRD3 | H4R3me2a; H3R17me2a; H3R2me2a | >500 | transcriptional coactivator and interacts with CARM1 and PRMT1 | 105, 109 |
Abbreviations: Kd, dissociation constant; N.D., not defined; ATM, Ataxia telangiectasia mutated; PRC2, polycomb repressive complex 2 Modifications: me1, monomethylation; me2, dimethylation; me3, trimethylation; me2a, asymmetric dimethylation.
Protein domains: UBA, ubiquitin-associated domain; JmjN, jumonji N domain; JmjC, jumonji C domain; PHD, plant homeodomain; BRCT, BRCA1 C terminus domain; UBL, ubiquitin-like domain; SRA, SET and RING finger associated domain; RING, really interesting new gene finger domain.
for PHF1 or PHF19 binding to H3K36me3 peptides, a Kd of 5~6 μM was obtained at 4 degree in a buffer of 100 mM NaCl and 20 mM Tris-HCl pH 7.5, and a higher Kd of 35–50 μM obtained at 25 degree in a buffer of 150 mM NaCl and 20 mM Tris, pH 6.8–7.5.